Q1 I routinely assess the ocular surface health of my glaucoma patients.
[Select one] (Hereafter abbreviated as “Strongly Disagree – Strongly Agree”) o Strongly disagree
o Disagree
o Somewhat disagree o Neither agree nor disagree o Somewhat agree
o Agree
o Strongly agree
Q2 When assessing ocular surface health in glaucoma patients, I routinely (ie. in most or all patients) assess the following:
[Select all that apply or "None of the above"]
☐ Ocular surface symptom questionnaire (ie. OSDI)
☐ Schirmer testing
☐ Fluorescein staining
☐ Tear break-up time (TBUT)
☐ Lid position (entropion, ectropion, floppy eyelids, etc.)
☐ Lid health (presence of anterior or posterior blepharitis, rosacea, allergies, etc.)
☐ Meibomian gland health (secretion quality, dropout, etc.)
☐ Conjunctival health (ie. injection, papillae, scarring, etc.)
☐ None of the above
Q3 I routinely use a classification system (e.g. DEWS, NEI, etc) to grade the ocular surface health of my glaucoma patients.
[Select one] Strongly Disagree – Strongly Agree
Q4 In the past year, I have consulted a specialist in ocular surface health (ie. Cornea) to assist with ocular surface management in glaucoma patients with ocular surface disease.
[Select One]
o Never o Rarely o Sometimes o Often
o Almost Always
Q5 When treating ocular surface disease in glaucoma patients, I feel knowledgeable with respect to the role and use of the following modalities:
[Select all that apply or "None of the above"]
☐ Lid hygiene (ie. scrubs)
☐ Lid compresses and massage
☐ Omega 3 oral supplementation (including specific dosages)
☐ Serum tears
☐ Topical corticosteroids
☐ Artificial tears
☐ Optimizing topical therapies (switching to combination gtts, unpreserved or non-BAK formulations)
☐ Topical immunomodulators (ie. cyclosporine 0.05% or lifitegrast 5%)
☐ None of the above
Q6 I feel knowledgeable with respect to the available non-BAK containing topical glaucoma medications.
[Select one] Strongly Disagree – Strongly Agree
Q7 I feel knowledgeable with respect to the use of serum tears for the treatment of ocular surface disease in glaucoma.
[Select one] Strongly Disagree – Strongly Agree
Q8 Patients receiving glaucoma treatment in non-glaucoma ophthalmology practices (ie. Comprehensive or otherwise) receive adequate management of ocular surface disease prior to referral to my practice.
[Select one] Strongly Disagree – Strongly Agree
Q9 The ocular surface health of glaucoma patients is presently being adequately managed in subspecialty (tertiary) glaucoma practices.
[Select one] Strongly Disagree – Strongly Agree
Q10 I feel knowledgeable with respect to the different topical steroid preparations available (including respective dosages) for the treatment of ocular surface disease in general.
[Select one] Strongly Disagree – Strongly Agree
Q11 I feel knowledgeable with respect to the different topical steroid preparations available (including respective dosages) for the treatment of ocular surface disease in my glaucoma patients.
[Select one] Strongly Disagree – Strongly Agree
Q12 I feel comfortable identifying glaucoma patients with ocular surface disease who may benefit from a course of topical steroids.
[Select One] Strongly Disagree – Strongly Agree
Q13 When considering further treatments for glaucoma, I often consider ocular surface health while choosing the next step.
[Select one] Strongly Disagree – Strongly Agree
Q14 When considering further treatments for glaucoma, I often anticipate their effects on ocular surface health and take pre-emptive steps to mitigate them (ie. prescribing or increasing ocular surface disease measures).
[Select one] Strongly Disagree – Strongly Agree
Q15 I feel knowledgeable as far as current recommendations for omega supplementation for the treatment of ocular surface disease, including specific dosages.
[Select one] Strongly Disagree – Strongly Agree
Q16 When treating ocular surface disease in glaucoma, my approach is highly individualized with respect to the available treatment options (artificial tears, steroids, omega 3 supplementation, serum tears, cyclosporine, etc.).
[Select one] Strongly Disagree – Strongly Agree
Q17 When first addressing ocular surface disease among my glaucoma patients requiring topical medications, the top 3 modalities used in my practice are:
[Select up to 3, or specify under "other"]
☐ Warm compresses
☐ Lid hygiene
☐ Omega 3 supplementation
☐ Artificial tears (preserved or unpreserved)
☐ Optimizing topical medications (ie. combination, preservative free, or non-BAK formulations)
☐ Topical corticosteroids
☐ Topical immunomodulators (ie. cyclosporine 0.05%, lifitegrast 5%)
☐ Other (please specify): ___________________________________
Q18 A suggested algorithm for the treatment of ocular surface disease in glaucoma, including recommended timing and doses of therapies such as artificial tears, serum tears, BAK-free preparations, topical steroids or other potential anti-inflammatory agents, could improve my approach to surface disease in glaucoma.
[Select one] Strongly Disagree – Strongly Agree
Q19 Comprehensive management of ocular surface disease in glaucoma patients could lead to better glaucoma outcomes.
[Select one] Strongly Disagree – Strongly Agree
Q20 Comprehensive management of ocular surface disease could improve the quality of life of patients in tertiary glaucoma practices.
[Select one] Strongly Disagree – Strongly Agree
Q21 Please select the highest level of formal glaucoma training you have completed.
[Select one or specify under "Other"]
o Comprehensive Ophthalmology Training (Residency in Ophthalmology) o Glaucoma Fellowship Training
o Other (Please Indicate): ________________________________________________
Q22 In which province or territory do you primarily practice?
[Select one]
Q23 How many years have you been in unsupervised practice (ie. outside of residency and fellowship training)?
[Select one]
o Under 5 years o 5 to 14 years o 15 to 24 years o 25 or more years
